Literature DB >> 11703391

Inflammation as a key event in the development of neointima following vascular balloon injury.

C L Wainwright1, A M Miller, R M Wadsworth.   

Abstract

1. The present review discusses the current evidence to implicate leucocytes as key players in the development of neointima in arteries that have been subjected to balloon angioplasty injury. 2. There is substantial clinical evidence that leucocytes are activated after angioplasty, as determined by increased plasma levels of both leucocyte granulation products and soluble leucocyte and endothelial cell adhesion molecules. 3. Experimental evidence to implicate leucocytes in neointimal formation comes from studies that demonstrate leucocyte accumulation occurs within the vascular wall soon after injury and that induction of leukopenia prevents neointimal formation. 4. The evidence implicating specific adhesion molecules and cytokines in the key events leading to neointimal formation is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703391     DOI: 10.1046/j.1440-1681.2001.03543.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  12 in total

1.  Adjunct Use of a Self-expanding Stent for Treatment of Intracranial Stenosis. A Case Report.

Authors:  N Fujimura; H Yilmaz; G Abdo; K O Lovblad; R Sztajzel; D A Rüfenacht
Journal:  Interv Neuroradiol       Date:  2005-10-26       Impact factor: 1.610

Review 2.  Submaximal angioplasty and staged stenting for severe posterior circulation intracranial stenosis: a technique in evolution.

Authors:  Elad I Levy; Jay U Howington; Johnathan A Engh; Ricardo A Hanel; Naveh Levy; Stanley H Kim; Kevin J Gibbons; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Self-expanding stent-assisted middle cerebral artery recanalization: technical note.

Authors:  Eric Sauvageau; Elad I Levy
Journal:  Neuroradiology       Date:  2006-04-19       Impact factor: 2.804

4.  Exploring the molecular mechanisms of OSU-03012 on vascular smooth muscle cell proliferation.

Authors:  Wei-Wen Kuo; Jing-Ru Weng; Chih-Yang Huang; Chang-Hai Tsai; Wei-Hung Liu; Cheng-Hao Wen; Shih-Chang Tsai; Chieh-Hsi Wu
Journal:  Mol Cell Biochem       Date:  2010-07-13       Impact factor: 3.396

Review 5.  Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies.

Authors:  Akihito Muto; Lynn Model; Kenneth Ziegler; Sammy D D Eghbalieh; Alan Dardik
Journal:  Circ J       Date:  2010-07-01       Impact factor: 2.993

Review 6.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

7.  Vascular smooth muscle cell-derived transforming growth factor-β promotes maturation of activated, neointima lesion-like macrophages.

Authors:  Allison Ostriker; Henrick N Horita; Joanna Poczobutt; Mary C M Weiser-Evans; Raphael A Nemenoff
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-13       Impact factor: 8.311

8.  Complications of Neuroform stent in endovascular treatment of intracranial aneurysms.

Authors:  Abutaher M Yahia; Vickie Gordon; John Whapham; Ali Malek; J Steel; Richard D Fessler
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

9.  Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells.

Authors:  Shui Xiang; Nian-Guo Dong; Jin-Ping Liu; Yu Wang; Jia-Wei Shi; Zhan-Jie Wei; Xing-Jian Hu; Li Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-10-20

10.  Lysosome-dependent Ca(2+) release response to Fas activation in coronary arterial myocytes through NAADP: evidence from CD38 gene knockouts.

Authors:  Fan Zhang; Min Xia; Pin-Lan Li
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-03       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.